Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high
A common clinical phenotype arising from diverse pathogenic mechanisms. Study of PBMC transcriptomes (ACPA+ at-risk vs early ACPA+ RA vs controls). A TF signature was enriched in early RA & at-risk individuals (involving SUMOylation, RUNX2, YAP1, NOTCH3, β-Catenin). Cells w/… https://t.co/vCDEjIMXWa https://t.co/mizo7AXWvr
Dr. John Cush @RheumNow( View Tweet )
At RWCS 2025, Dr. Susan Shenoi aptly noted the prevalence of multisystem inflammatory syndrome in children (MIS-C) has declined significantly. Does this indicated herd immunity or the decline of community SARS-CoV-2 (or both)? @ShenoiSusan https://t.co/vY01VDkNVl… https://t.co/c8Qu4OqBSh https://t.co/yZAoRcG6LN
Dr. John Cush @RheumNow( View Tweet )
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
https://t.co/ZsS3JOqdLh https://t.co/3JByNrLTGR
Links:
Dr. John Cush @RheumNow( View Tweet )
8 fold risk of incident ILD in #RA pts. Data from Korean National Health Insurance, 52,325 RA pts & 261,625 controls & 4.4 yrs F/U - ILD in 3.7% of RA vs 0.5% controls (adjHR 7.84); higher in seropositive RA (aHR= 9) vs seronegative RA (aHR=4.8) https://t.co/iIoZOwFYEN https://t.co/HBzSg9KrpZ
Dr. John Cush @RheumNow( View Tweet )
EGPA in 2025
Eosinophilic Granulomatosis with Polyangiitis (EGPA), the artist formerly known as Churg-Strauss syndrome, remains somewhat of a rogue agent among the vasculitides.
https://t.co/4ofjQRYsMH https://t.co/PoVhaQ9QiZ
Links:
Dr. John Cush @RheumNow( View Tweet )
The POWER of #plaquenil
#Hydroxychloroquine works in #rheumatic #diseases by
Old answer
👇
Alters liposomal membranes 🤷♀️
NEW ANSWER
Inhibits TLR signalling 🔥
#RNL2025 Mary *Peggy Crow #SLE #systemic #lupus #erythematosus https://t.co/j2YQjVIpcy
Dr. John Cush @RheumNow( View Tweet )
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk
Dr. John Cush @RheumNow( View Tweet )
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA
Richard Conway @RichardPAConway( View Tweet )
Different types of IFNs have different actions and signaling pathways. Dr. Crow #RNL2025 @rheumnow https://t.co/1lJFwlhO92
TheDaoIndex @KDAO2011( View Tweet )
Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)?
-LORA pts tend to present acutely
-High inflammatory markers~PMR Like
-Seronegative/Decreased titers of RF/CCP
@UnaMakris
#RNL2025 @RheumNow https://t.co/aOCwb3lHef
Adela Castro @AdelaCastro222( View Tweet )
Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more… https://t.co/y50uCU79i9 https://t.co/crKytLY4WN
Dr. John Cush @RheumNow( View Tweet )
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
Granzyme - a major driver of inflammatory & autoimmune diseases
EurekAlert!
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury. Now, over 100 years after the
Read Article
Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Read Article
Congratulations to 2025 Crafoord Prize (in Polyarthritis) laureates Christopher Goodnow, (UNSW Sydney, Australia), and David Nemazee (Scripss,, USA) for their work on tolerance checkpoints - prevent B cells from attacking the body’s own tissues in autoimmune diseases… https://t.co/WSyXVIFJa1 https://t.co/JtBau2JSvo
Dr. John Cush @RheumNow( View Tweet )
Epidemiology of idiopathic inflammatory myopathies (IIMs) has incidence rates ranging from 0.2 to 2 cases per 100 000 person-years. https://t.co/tUWpijtKWX https://t.co/Mb66cZ1Aga
Dr. John Cush @RheumNow( View Tweet )
Palmar fasciitis & polyarthritis syndrome (PFPAS). JAMA case 50yoM w/ progressive hand swelling, stiffness, thickening, erythema, hepato-splenomegaly. Skin Bx dermal fibrous tissue. WBC 152k, LDH 889, lead to CML dx made by BM Fx (myeloid-erythroid ratio 21 w/ myeloblasts). +… https://t.co/xtHbzAioss https://t.co/RfMrfntFtb
Dr. John Cush @RheumNow( View Tweet )
Lung Involvement in Still's Disease
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.… https://t.co/rGYEgCeUDA https://t.co/fdUGvfU8HH
Dr. John Cush @RheumNow( View Tweet )
Functional Precision Medicine in Rheumatoid Arthritis
Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.
Read Article
Congratulations to Jennifer Anolik, MD, PhD, being named chief of the Allergy, Immunology & Rheumatology at the Univ. of Rochester Medical Center; where she is also Assoc Chair of research & professor of Medicine, Pathology, Microbiology and Immunology, and director of the… https://t.co/jvRiZZ6u1q https://t.co/N2nFp8w6Yx
Dr. John Cush @RheumNow( View Tweet )
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush @RheumNow( View Tweet )
Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).
Read ArticleRecent Blogs
